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1. Introduction 
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central 
nervous system (CNS) and the primary cause of non-traumatic neurologic disability in the 
western world. Infiltration of myelin-specific effector T cells into the CNS is thought to 
cause demyelination and loss of axons resulting in deficient signal conduction and clinical 
onset of the disease. Although previously thought to be initiated by T helper 1 (Th1) cells, it 
has become evident that Th17 cells are also involved (Cua 2003). In addition, CD8+ T cells, 
macrophages, and B cells are also found in inflammatory infiltrates in the CNS of affected 
individuals. During the initial phases of the disease, once the myelin-specific peripherally 
activated T cells penetrate the CNS, they are re-activated by antigen presenting cells 
presenting their target antigen within the CNS and act to cause damage to axonal myelin 
through the activation of macrophages and the release of myelin toxic substances (Aktas, 
Waiczies et al. 2007). 
One of the main obstacles to recovery and to the treatment of MS is the relatively low 
efficiency of spontaneous remyelination of axons by oligodendrocytes. In the majority of 
cases during the early phases of the disease a large amount of oligodendrocytes and their 
precursors are preserved within the characteristic demyelination plaques and retain the 
ability to remyelinate. Despite this resident population of remyelinating cells it has been 
shown that over time remyelination becomes incomplete and fails, resulting in the 
irreversible neurological damage associated with the disease (Franklin 2002). 
The direct cause of MS remains unknown but it seems most likely to be a mixture of both 
genetic susceptibility and environmental factors. Genetic factors had been long suspected to 
affect the chances of an individual developing MS. It has been known for some time that 
there is a familial link to the disease with a sharp increase in disease probability if a family 
member has the disease (Dyment, Ebers et al. 2004), with a direct correlation between how 
closely related the affected individual is and the probability of developing the disease. The 
importance of genetic factors was underscored by the fact that adopted children have no 
statistically significant increase in there disease susceptibility compared to the general 
population, even if any of their adoptive family members have the disease. Other genetic 
factors such as gender and race have also been shown to have an effect (Sospedra and 
Martin 2005). 
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More recently environmental factors have been highlighted by an increase in MS cases in 
westernised society as opposed to that of other less developed areas of the world. It is 
thought this may be due to the lack of exposure to infection during adolescence and 
childhood and has been highlighted in places such as Japan (Li, Chu et al. 2007) where a 
strong link may exist between the number of MS cases and the increase in sanitation. 
Among infectious environmental factors, Epstein Barr and other human Herpes viruses 
have received most attention in recent years (Levin, Munger et al. 2010). Other non-
infectious environmental factors, such as latitude and sun exposure have also been linked to 
the disease (Sospedra and Martin 2005).  
Current treatments for MS include IFN-┚, glatiramer acetate and mitoxantrone which show 
some degree of efficacy and have potential side effects (Markowitz 2010). New more 
effective treatments for MS are highly desirable, in particular those able to slow disease 
progression in addition to reducing the frequency of clinical exacerbations. Although 
several pharmacological therapies are in clinical trials or have recently been approved (such 
as the immunosuppressive drug Fingolimoid, (Cohen and Chun 2011)), cellular treatments 
are attractive alternatives. They may theoretically possess the ability to modulate the 
immune response but also enhance spontaneous remyelination of damaged axons and thus 
limit or even reverse the irreversible neurological damage associated with MS. The 
challenge is making this theoretical potential become a reality. 
 
 
 
Fig. 1. Potential roles for different types of stem cells in the treatment of MS [Adapted from 
(Martino, Franklin et al. 2010)]. 
2. Stem cell therapies 
Stem cells are the most promising treatment option in cellular therapy as they have the 
potential to differentiate into a multitude of cells. There are several types of stem cells which 
are isolated from different types of tissue which include embryonic, mesenchymal, 
hematopoietic and neuronal stem cells along with the relatively new discovery of fibroblast 
derived induced pluripotent stem cells (IPS). These different phenotypes of stem cells hold 
great potential in the treatment of a variety of different conditions and potentially have a 
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range of positive effects on MS and a range of other inflammatory, traumatic and 
neurodegenerative CNS conditions. The fact that stem cells possess the theoretical ability, 
under the right conditions, to differentiate into any type of cell in the body makes them a 
very desirable treatment option. However significant issues arise with their use including 
ethics, access to the cells, and their potential side effects.  
2.1 Embryonic stem cells 
Of all the different types of stem cells, embryonic stem cells (ESC) have the largest 
differentiating potential and are also the best categorised but despite this their use has come 
up against a variety of practical and ethical hurdles due to their embryonic source. 
Theoretically embryonic stem cells can provide an unlimited supply of cells with vast 
differentiation potential. In animal models and in the right environment, they can be 
directed into differentiating into oligodendrocytes and successfully undertaking 
remyelination (Nistor, Totoiu et al. 2005). This remyelination has been shown in a number of 
animal models following the infusion of ESC derived glial precursors leading to a significant 
degree of remyelination in both the spinal column and the brain (Brustle, Jones et al. 1999). 
It has also been noted that the time of infusion with these cells is crucial, with some studies 
showing that, in the case of spinal injury, remyelination is much more effective if the 
embryonic stem cell derived cells are introduced soon after the damage (7 days) as opposed 
to later after the event (10 months) (Keirstead, Nistor et al. 2005). This suggests that in the 
case of neurodegenerative disease these cells may be more effective if transplanted in the 
earlier stages of the condition.   
Not only do embryonic stem cells show the potential to remyelinate but also have an effect 
on EAE through the modulation of the immune system, with a number of animal models 
showing a down regulation of the auto-immune T-lymphocyte response against self antigen 
(Fandrich, Lin et al. 2002). This immunomodulatory potential has been proposed to be 
through both contact-dependent mechanisms and the release of soluble factors. For example 
PGE2 was identified as one of these factors in murine models in which embryonic stem cells 
had been used to dampen the immune response in organ transplantation (Imberti, Casiraghi 
et al. 2011). 
Despite the promising potential of embryonic stem cells as a therapy for multiple diseases 
and conditions there are several hurdles which realistically may never be fully overcome. 
The first of these are the ethical ramifications of work involving embryonic stem cells. The 
fact that embryonic stem cells would most likely have to be sourced from human embryos 
has raised serious concerns about the use of sources of ‘potential life’ as a research tool. To 
date, much of the work in stem cell research has been conducted using unwanted embryos 
originally produced for IVF treatment. However, if this became a main stream treatment 
embryos would have to be produced for the specific purpose of producing appropriate stem 
cells, which many see as unethical (de Wert and Mummery 2003). Another ethical hurdle 
would be the production of autologus stem cells where the nucleus from the cell of the 
patient would be infused into a de-nucleated oocyte in order to create a strain of stem cells 
specific to the patient which would help to bypass the issue of rejection (de Wert and 
Mummery 2003). Many believe the specific use of embryonic stem cells is not the issue; it is 
the precedent it would set. The ethical debate surrounding ESC is unlikely to be easily 
resolved. 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
358 
Another issue surrounding embryonic stem cells is safety. The use of heterologus embryonic 
stem cells carries the risk of the formation of teratoma (tumour) within the specific organ of 
transplantation (Bjorklund, Sanchez-Pernaute et al. 2002; Blum and Benvenisty 2008). 
Altering the cells to reduce this risk may prove very difficult and may also have a 
detrimental effect on the cells’ ability to exert the therapeutic purpose for which they are 
intended.  This issue can be avoided with the use of autologus stem cells (mentioned above) 
but this leads to not only ethical but also practical issues, with every patient being treated 
having to be cloned to produce the stock of autologous cells for treatment. 
2.2 Adult neuronal stem cells 
Adult neural stem cells (aNSC) do not carry the same ethical burden as embryonic stem cells 
and have shown the ability to both remyelinate demyelinated axons and modulate the 
autoimmune response.  These cells are generally isolated from the adult mammalian sub 
ventricular zone (SVZ), which makes them difficult to extract and use for clinical purposes. 
They can be maintained for extended periods in vitro and still retain the ability to 
differentiate and proliferate (Nunes, Roy et al. 2003). In EAE it has been documented that 
aNSC can act to aid the disease both through remyelination and through an 
immunomodulatory effect. In terms of remyelination, aNSC have been proposed as 
treatments for a multitude of different conditions such as neurodegenerative disorders 
including MS (Magalon, Cantarella et al. 2007), CNS traumas (Iwanami, Kaneko et al. 2005) 
and malignant tumours. Transplanted cells have been shown to migrate from the area of 
infusion to the area of inflammation (Ben-Hur, Einstein et al. 2003) especially within the 
white matter of the CNS, with the labelling of infused cells showing that 80% of lesions 
contain labelled cells within 24 hours of infusion (Politi, Bacigaluppi et al. 2007). aNSC are 
also seen to be durable within the body with labelled cells still detected within lesions 20 
days after infusion (Politi, Bacigaluppi et al. 2007). Along with the detection of aNSC 
presence and migration visualised by cell labelling, remyelination and cell replacement have 
also been visualised in EAE with the use of electron microscopy (Pluchino, Quattrini et al. 
2003). aNSC’s have been shown to migrate to areas of demyelination (and not to areas of 
normal looking brain and CNS matter) and differentiate into oligodendrocytes capable of 
remyelination and thus attenuate the clinical symptoms of EAE within the tested animals. 
In terms of the immunomodulatory effects of aNSC on neurodegenerative diseases such as 
MS there has been some debate. It has been shown that animals given an IV injection of 
aNSCs in the early stages of EAE show a significant immunosuppressive effect. Animals 
treated with aNSCs were shown to have a gathering of the infused cells at the spleen and 
lymph nodes and here had a profound effect on the immune response to self CNS antigen 
through their interaction with the T-cell populations in these areas (Einstein, Fainstein et al. 
2007). T-cells isolated from the lymph nodes of mice that had been infused with aNSC’s 
showed no activation in the presence of either CNS specific antigens or other non-specific 
stimulus (Einstein, Fainstein et al. 2007). It is evident that these cells, when injected 
intravenously at the early stages of the disease, do not penetrate the CNS or get attracted to 
areas of inflammation like aNSC’s injected at the height of the disease but travel to areas of 
immune regulation such as the spleen and lymph nodes where they have an dampening 
effect on the peripheral immune response (Ben-Hur 2008). 
The key to the use of aNSC’s in therapy will be optimising the technique to allow both the 
immunomodulatory and the remyelinating features of the treatment to work in tandem and 
thus have a greater effect on the symptoms of the disease. aNSCs have several advantages 
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over other forms of stem cells, including fewer ethical burdens, maintaining differential and 
proliferative ability over long periods of time, and having both immunomodulatory and 
remyelinating potential. Therefore, they are one of the more promising avenues of 
investigation into MS treatments. They also seem to pose little risk of tumour formation, 
which is in stark contrast to a number of other stem cell types. In all the aNSC transplant 
studies in both healthy and diseased animals there have been no instances of tumour 
formation which suggests that the potential use of this treatment in vivo would carry little if 
any risk in the way of tumour development.  
2.3 Mesenchymal stem cells 
Mesenchymal stem cells are stromal stem cells which can be isolated from a variety of adult 
tissues but predominantly from the bone marrow. The therapeutic effect of these cells on 
neurodegenerative diseases has previously been based mainly on immunomodulation, but 
recently it has been proposed that these cells may be able to induce axon remyelination. 
However, this is yet to be unequivocally proven. In terms of immunomodulation, bone 
marrow isolated mesenchymal stem cells are known to have a dampening effect of the 
autoimmune response to CNS self antigens in EAE. The mesenchymal cells are shown to 
have an inhibitory effect on the activation of encephalitogenic T cells primed against self 
CNS antigen, thus reducing disease severity (Kassis, Grigoriadis et al. 2008). T-cells isolated 
from MSC-treated animals show a reduced ability to produce inflammatory cytokines (such 
as IFN- and TNF-┙) and do not proliferate in the presence of the EAE-inducing CNS self 
antigen (Gerdoni, Gallo et al. 2007). In addition to reducing T-cell function, MSCs can also 
modulate the proliferation and maturation of antigen presenting cells (APC) (Beyth, 
Borovsky et al. 2005), which in turn affect T-cell priming to self antigens. 
The potential for the infusion of mesenchymal bone marrow derived stem cells to induce a 
degree of remyelination in animal models of MS has been reported in a few studies. Such 
cells removed from the bone marrow of donor mice and cultured in vitro were infused into 
damaged EAE spinal cords and induce both central and peripheral myelination (Akiyama, 
Radtke et al. 2002). 
Bone marrow stem cells can also be used as a source of neural cells, bone marrow-derived 
neural stem cells. These cells are phenotypically identical to aNSC isolated from the SVC 
and express the neural stem cell marker nestin. Like aNSC’s and unlike other stem cells 
isolated from the bone marrow, these cells show the ability to migrate into the CNS and 
differentiate into both oligodendrocytes and neurons at sites of CNS damage, such as 
inflammatory CNS lesions in MS (Kabos, Ehtesham et al. 2002). However, their 
differentiation into cells capable of remyelination is not the only way these cells are said to 
act in the repair of damaged axons. They may also promote remyelination by pre-existing 
cells through the release of growth factors. Bone marrow derived neuronal cells also seem to 
have significant immunomodulatory properties, such as in vitro suppression of T cells, B 
cells and natural killer (NK) cells.  
2.4 Haematopoietic stem cells 
Hematopoietic stem cells (HSC) have been extensively studied for immune replacement 
therapy in aggressive forms of MS. There are a number of advantages to this form of stem 
cell which is why research into it has been so thorough. The isolation process compared to 
that of other stem cells is less invasive and more ethically acceptable as the CD34+ cells can 
be easily isolated from peripheral blood. HSC transplantation (HCST) may be one of the 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
360 
most potent available forms of immunotherapy; however issues of safety have limited the 
advance of this approach into clinical use. Useful predictors of good therapeutic outcomes 
after HSCT include rigorous selection of the most suitable patients for this type of treatment 
and the specific treatment protocol. Patients with low to intermediate level of disability 
experiencing active relapses despite treatments with IFN-beta or with more potent 
immunosuppressive drugs, such as mitoxantrone, may show a better risk/benefit ratio than 
those with advanced, secondary progressive disease with higher disability (Muraro, 
Cassiani Ingoni et al. 2003; Burt, Cohen et al. 2005). The regime of treatment is also vital to 
the success of the treatment with early studies, which used myeloblative transplantation 
regimes, suffering high levels of toxicity and mortality (Burt, Cohen et al. 2005). The use of 
revised, non myeloblative HSCT conditioning protocols, seems to have had a positive effect 
on the mortality rates associated with the previous treatment regimes. 
There are many issues when using hematopoietic stem cells as a treatment option in MS 
involving both ethics and safety. The risk involved in HSCT is relatively high although 
safety has increased over recent years. An example is the drop in mortality rate in patients 
suffering from autoimmune conditions treated with autologus hematopoietic stem cell 
transplantation, which was 7.3% between 1995 and 2000 and dropped to 1.3% in the period 
from 2001-2007 (Schippling, Heesen et al. 2008). The direct effect of the hematopoietic stem 
cells in giving rise to malignant tumours is an obvious risk but another major issue is the 
level of immunosupression needed during a stem cell transplantation, which leaves the 
patient particularly vulnerable to infections. The risk factors in this type of 
immunosuppressive therapy make it a last resort, with patients and treating physicians 
having to assess and discuss the risk/benefit ratios of such a treatment before undertaking 
it. Considering that many patients with MS live for many years and can, to some degree, 
manage and slow the progression of their illness with pharmaceutical treatments, it may be 
hard to justify a therapy such as AHSCT. However, as the methods and techniques involved 
in AHSCT improve and the favourable outcomes seen in animal models are translated into 
human studies (this has already been seen in the limited number of humans successfully 
treated with the method), this treatment could in time become a key immunomodulation 
technique in treating MS. As these issues are overcome large scale, long term, controlled 
studies will be necessary to test the true efficacy of the treatment (Mancardi and Saccardi 
2008) after which HSCT treatment may be deemed safe for larger scale use. 
2.5 Induced pluripotent stem cells 
Induced pluripotent stem cells (IPS) are possibly the most exciting development in the field 
of stem cell therapy for the last few years. A group in Japan has shown that it is possible to 
generate pluripotent stem cells from fibroblast cultures with the addition of just 4  
transcription factors (Oct 3/4, Sox2, Klf4 and c-Myc) under ESC culturing conditions 
(Takahashi, Tanabe et al. 2007). These cells represent a significant step forward as they share 
the morphology and many functional properties with ESCs but can be generated from 
fibroblasts in the laboratory. The accessibility of fibroblasts, the comparatively straight 
forward techniques involved in generating IPS and the removal of important ethical 
burdens suggests an enormous treatment potential for such a type of stem cells. These cells 
could become a valid treatment option in regenerative medicine not only in MS but a variety 
of other inflammatory, neurodegenerative, and traumatic diseases including spinal cord 
injury, juvenile diabetes (Thomson, Itskovitz-Eldor et al. 1998) and potentially many others. 
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Despite their enormous potential, IPS do raise a number of safety concerns which must be 
overcome before they are considered as a valid treatment in humans. Due to a large number 
of retroviral integration sites (retroviruses are used to insert the relevant transcription 
factors into target cells to induce IPS) on IPS for each of the stimulating factors they may be 
prone to tumourigenesis. Mouse studies showed around 20% rate of tumour formation 
which is thought to be due to the reactivation of the c-Myc oncogene by retrovirus (Okita, 
Ichisaka et al. 2007). Tumour formation caused by retroviral integration is a serious issue 
which must be solved before this treatment is considered in the clinic.  
Other problems must be resolved as well. The yield of IPS cells from human fibroblast 
cultures is very low, which could represent a practical obstacle to the development of IPS as 
a treatment. The precise nature of IPS and their origin is still a matter of debate. Different 
theories suggest that the cells induced into IPS are actually undifferentiated stem cell-like 
cells within the fibroblast cultures. It is also possible that undetectable genetic alterations in 
the cells of origin may be required for IPS induction (Takahashi, Tanabe et al. 2007). For now 
these cells are a very useful tool within the process of understanding disease mechanisms 
and toxicology ex-vivo however the ultimate goal must be to develop this therapy to a point 
where it can be used to treat human conditions. Considering that these cells were only 
discovered in 2007, research into this form of pluripotent cells is still at an early stage. As 
time progresses it is likely some of the issues surrounding these cells will be overcome, and 
along with a better understanding of the mechanisms behind these cells they may become a 
valid treatment option in human medicine. 
In summary, stem cells treatments are, and have been for some time, one of the most 
promising and exciting potential treatment options within human medicine. Thus far, they 
have failed to fulfil this immense promise having been held back by many ethical, practical 
and safety related hurdles. Nevertheless, stem cell research is constantly moving forward. 
With the discovery of new treatment protocols and new types of promising cells, such as 
IPS, the time when stem cells become a front line treatment for immunomodulation and 
neural regeneration in MS may be closer than ever. 
3. Non-stem cell cellular therapies 
It is not only stem cells which have been identified as a potential treatment option for 
patients suffering from MS. There are a range of possible cellular treatments which involve 
the infusion of cells isolated from the body with aims varying from halting the progression 
of the disease through immunomodulation to the active re-myelination of affected axons. 
Non-stem cell treatments would include the infusion of peripheral nervous system 
myelinating Schwann cells into the CNS as well as the use of ex vivo cultured 
oligodendrocytes, olfactory ensheathing cells and even cells isolated from the body’s 
immune system such as T-cells.  
3.1 Oligodendrocyte and oligodendrocyte precursor cells 
Myelination of axons within the CNS is typically the task of oligodendrocytes and their 
precursors during development and in response to damage, however it has been shown that 
a significant proportion of these cells are lost or are deemed functionally inactive in MS, 
particularly in chronic phases of disease. It has been suggested that the reason for this 
decrease in numbers of oligodendrocytes is due to either the lack of differentiation of 
precursor cells into mature oligodendrocytes or the death of the oligodendrocytes once they 
reach a certain point within the developmental process (Wolswijk 2000).  
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There is a degree of debate over the stage at which oligodendrocyte precursor cells (OPC) 
are most effective at myelinating axons along there maturation process. It is thought that 
oligodendrocyte progenitor cells are responsible for generating the largest amount of myelin 
over the widest area and are more proficient than mature oligodendrocytes (Franklin 2002; 
Wolswijk 2002). There is evidence that mature oligodendrocytes when infused into a 
demyelinated CNS environment are less capable of migration and division at the site of 
demyelination than the more motile and proliferative oligodendrocyte progenitor cell. 
Another advantage of OPCs is their ability to react to their microenvironment. The path of 
maturation of these cells is affected by cytokines, chemokines and growth factors causing 
their maturation to a cell with remyelinating potential “in the right place at the right time”, 
which is also aided by enhancement of the signalling matrix and removal of phagocytic 
debris by inflammatory cells (Zawadzka and Franklin 2007). 
3.2 Schwann cells 
Schwann cells, typically responsible for myelination within the peripheral nervous system, 
are seen as an alternative to oligodendrocytes and OPCs in the cellular treatment of MS and 
have been shown to be capable of a significant degree of axonal remyelination within the 
CNS of MS patients (Lavdas, Papastefanaki et al. 2008). Despite the issues surrounding the 
use of these cells, such as their inability to interact with astrocytes and limited survivability 
within the CNS, their ability to remyelinate axons and improve axonal conduction in 
damaged axons is not in doubt. The question is whether they can do so to such a degree that 
it is an effective and worthwhile treatment option for patients with MS. Schwann cells have 
been proposed as a treatment for CNS damage not only for MS but for other pathological 
conditions including the repair of spinal cord injury (Oudega 2007) where their proposed 
function to aid the remyelination of damaged axons remains the same. There are many 
positive and negative aspects to Schwann cells as a potential cellular treatment option in 
MS, with the main advantage being the ease of accessibility from peripheral nerve biopsies 
and thus the relatively simple task of culturing autologus populations of these cells. Another 
positive aspect is that they are less likely than oligodendrocytes to be prone to MS related 
autoimmune attack as this tends to be against the CNS myelinating cells due to being 
targeted towards mature oligodendrocyte antigens (Kohama, Lankford et al. 2001). On this 
note, the myelin they produce is also less likely to be susceptible to autoimmune attack due 
the slight differences in its make up as compared with the myelin produced by 
oligodendrocytes. Due to the autoimmune attack in the CNS being focused against antigens 
within the oligodendrocyte produced myelin, the subtle differences in the makeup of 
Schwann cell myelin makes it a less likely target.  
As we have explained, the fact that Schwann cells are not usually resident within the CNS 
has its advantages in terms of not being recognised in an autoimmune attack, however the 
fact that these cells are out of their usual environment also has some negative ramifications. 
Schwann cells do not tend to migrate to areas of inflammation within the white matter of the 
CNS due to the inhibitory effect that astrocytes have on them. Schwann cells and astrocytes 
cannot coexist which poses huge problems in the treatment of MS as the majority of 
demyelinated plaques contain large numbers of astrocytes. Astrocytes have a number of 
detrimental effects on Schwann cells, effecting both their successful migration into the CNS 
white matter (Iwashita, Fawcett et al. 2000) and their ability to remyelinate and survive 
(Shields, Blakemore et al. 2000) within damaged astrocyte rich areas. It is proposed that this 
negative effect on Schwann cells in mediated by the release of soluble factors from the 
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astrocytes (astrocyte conditioned medium reduced Schwann cell proliferation and 
remyelination (Guenard, Gwynn et al. 1994)) such as Ephrins (Afshari, Kwok et al. 2010) and 
also through a prolonged contact interaction between Schwann cells and the astrocytes 
mediated by N-Cadherin (Wilby, Muir et al. 1999). This limited ability to function within the 
CNS is a major drawback for the use of Schwann cells as a remyelinating treatment as any 
effect they do have will be short lived due to the short time span they can survive within the 
appropriate system. If Schwann cells are to become a widely used remyelinating treatment 
option in the treatment of MS work will have to be done to produce a Schwann cell-based 
therapy capable of migrating to sites of CNS inflammation and able to survive in the 
presence of astrocytes. Efforts are being made to improve the chances of Schwann cells 
surviving interaction with astrocytes through methods such as genetically altering the cells 
(Papastefanaki, Chen et al. 2007).  
3.3 Olfactory ensheathing cell 
Another type of cell that has been proposed for the remyelination of axons in multiple 
sclerosis is the olfactory ensheathing cell (OEC). These are a form of unique glial cell found 
only in the olfactory system close to the first cranial nerve. These cells are favourable over 
other cell based therapies for a number of properties, one of which is their ability to survive 
in the presence of astrocytes. Astrocytes are found around areas of MS induced CNS 
inflammation and as previously discussed are a major problem for Schwann cell therapy. 
OEC’s can survive in conjunction with astrocytes and can also make the environment 
around the CNS inflammation more hospitable to the migration and survival of endogenous 
Schwann cells (Boyd, Lee et al. 2004).  
Despite this ability to survive and retain function in the presence of astrocytes there are also 
some disadvantages to the OEC in the treatment of MS. Despite their ability to remyelinate 
axons and partially regenerate nerve fibres (Richter and Roskams 2008) they do not seem to 
have a great deal of the ability to cross the MS associated lesion and or to reconnect with 
neurons on the opposite side of the lesion. It is thought that due to this process of repair not 
being overly apparent most of the benefit for the use of OEC comes from the promotion of 
the growth of intact fibres. However, in the case of spinal injury it has been shown that, to at 
least some degree, these cells have the ability to stimulate neuroprotection, activate 
angiogenesis and stimulate axon re-growth as well as remyelination (Richter and Roskams 
2008). Another benefit of these cells is that in some cases they have been suggested to restore 
a degree of functions lost due to the CNS lesions. However, there is very little 
immunological data to support this conclusion, which was derived mainly from behavioural 
tests (Barnett and Riddell 2004). It is thought that the most useful way to utilise this type of 
cells may be to use them in parallel with other synergistic treatments. This would produce a 
combination treatment with the potential to regenerate axons but also reconnect the 
damaged connections across the compromised areas of the CNS which OEC alone are 
unable to do (Barnett and Riddell 2007). 
3.4 T-cell therapy 
Another cellular treatment for MS which differs from all the previous treatments as it does 
not involve remyelinating cells is T-cell therapy. When thinking of ways to tackle 
autoimmunity one of the most obvious candidates for cellular therapy has to be regulatory 
T-cells due to their role in maintaining immunological self tolerance within the body. This 
CD4+CD25+ cell surface marker positive family of cells within the body is in part to control 
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the immune response and therefore seem an obvious choice for cellular therapy for MS. It is 
known that in the peripheral blood of patients with MS there is a significant decrease in the 
functionality of T-regulatory cells (Viglietta, Baecher-Allan et al. 2004) when compared to 
healthy controls, which shows this may be a causative mechanism behind the disease and 
readdressing this balance may go some way to alleviating autoimmunity. 
 It has been shown in animal models that adoptive transfer of such T-regulatory cells has a 
positive effect on models of autoimmune disease (Jiang, Lechler et al. 2006), in some cases 
offering a significant degree of protection from the disease (Kohm, Carpentier et al. 2002) 
and therefore poses a degree of therapeutic potential in the treatment of MS. The therapeutic 
potential of these cells is based on their ability to suppress the function of auto reactive T 
helper cells in-vitro and to show a significant potential for in-vivo treatment as well. There is 
also the possibility of targeting these cells in-vivo with other drugs in an attempt to expand 
an antigen specific population of these cells to tackle the autoimmune response in the MS 
patients. 
Another form of T cell therapy which has been proposed is the use of inflammatory CD4+ T 
cells. These cells have long been thought to have little therapeutic potential in CNS 
autoimmunity but it has been proposed by a group in Israel that a lack of CD4+ immune 
cells recruited to the CNS may affect the immunological balance in the CNS further and 
exacerbate inflammation within the system (Schwartz and Shechter 2010). Their theory is 
that these CD4+ T cells must be recruited to the CNS to modify areas of local inflammation 
and also to aid the protective process through the recruitment of blood-borne monocytes 
(Schwartz, London et al. 2009). Many current therapies for MS involve treatment with 
immunosuppressive drug regimes which will strongly inhibit the ability of these 
inflammatory T cells to perform the proposed protective function and it has thus been 
proposed that a boost of such a T cell response to carefully chosen CNS proteins may act to 
improve and not hinder the immunological response against the localised inflammation. 
In summary, although cellular therapies for MS are often focused around stem cells, it is 
evident that non stem cell therapies have an important role to play. They do in most cases 
provide a safer, more ethical and more practical option of treatment compared to stem 
cells but may not posses as much treatment potential. However, this is not to say they are 
less effective than the treatments currently available. Like stem cells, the different types of 
these cells give non stem cell cellular therapies both remyelination and 
immunomodulatory potential. These cells have the potential to be used on their own or in 
combination with other therapies. With steps being taken to improve their efficacy (such 
as genetic alteration in the case of Schwann cells), they could become mainstream 
treatments in the fight against MS. 
4. Conclusion 
The devastating effect MS has on the lives of affected individuals and those close to them 
demands that this field of research be at the forefront of treatment development. The lack of 
current effective and curative therapies for this disease makes the advancement of cellular 
treatments all the more important as a new more effective line of treatment. The outstanding 
potential of cellular therapies to cover all bases in terms of treatment of MS including 
immunomodulation, neuroprotection and remyelination makes them impossible to ignore 
as they realistically have the most potential of any field of treatment currently available. 
Their potential is almost limitless with the variety of different effects the different cellular 
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treatments can have on the disease and how these could fit the needs of individual patients 
and their specific disease circumstances.  
The challenge to take these cellular therapies from being full of potential to being effective 
treatment options is one thousands of researchers around the world are working on every 
day. They strive to remove the issues which at the moment are holding back the clinical 
potential of these ‘shining light’ treatments in order to be able to offer patients diagnosed 
with MS hope that it may be possible to restore the myelin architecture within their CNS 
and to overcome the disease. The treatment options for MS are currently insufficient but the 
encouraging point is that the field is constantly moving forwards. With cellular based 
therapies at the forefront of this advancement it will give sufferers of the disease hope that 
better treatments and better prognosis may be just around the corner. 
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